Transcriptome comparison among patients, PDX, PDO, PDXO, PDXC and cell lines

Background: Patient-derived tumor models, e.g. patient derived xenograft (PDX), have been increasingly viewed as predictive preclinical cancer models for recapitulating features of patient tumors in molecular/histolopathology and pharmacology. Patient derived organoids (PDO), a 3-D culture of human tumor, have also been shown to maintain relevant structure and functions, as well as pharmacology. Both PDO and PDX are hence considered clinically relevant in vitro and in vivo models respectively. However, a systematic and comprehensive cross-examination of these two patient-derived models (including PDX-derived organoid, or PDXO), along with the traditional cell lines (including PDX-derived cells or PDXC) has yet to be undertaken. The present study sets out to systematically investigate the molecular pathology of the aforementioned cancer model libraries, along with cancer patient populations, using the available large datasets and statistical methodology.